Table 2. Distribution of subjects, samples and sequences in longitudinal analyses.

Longitudinal Data
Group	Subjects	Samples	Sequences
			V1V2	C2	V3	C3	V4	C4	V5
TOTAL	22	83	807	30	155	155	155	155	155
PIC	1	15	180	30	155	155	155	155	155
LANL	21	68	627	0	0	0	0	0	0
Sequences by category
Culture	NA	1	33	0	0	0	0	0	0
Cervical Swab	NA	7	37	0	0	0	0	0	0
PBMC	N/A	43	397	0	0	0	0	0	0
Plasma	N/A	32	340	30	155	155	155	155	155
Subtype A	2	26	172	0	0	0	0	0	0
Subtype B	20	57	635	30	155	155	155	155	155
Asia	4	9	102	0	0	0	0	0	0
East Africa	2	26	172	0	0	0	0	0	0
North America	12	40	440	30	155	155	155	155	155
Western Europe	4	8	93	0	0	0	0	0	0
Stage 1	NA	5	63	10	23	23	23	23	23
Stage 2	NA	12	140	10	111	111	111	111	111
Stage 3	NA	10	111	10	21	21	21	21	21
Stage 4	NA	9	86	0	0	0	0	0	0
Unknown Stage	10	47	407	0	0	0	0	0	0

Number of subjects, samples, and available coding sequences by cohort, gene region, anatomical site, HIV subtype, geographic location, and stage of illness.